
pm et
summari make diagnost product medic imag system surgic product
emphasi women health also make medic aesthet system
nm price-to-earnings oper ep
risk assess reflect particip
industri character rapid technolog chang new
industri standard new market entrant addit
compet number compani
significantli greater resourc product depth
includ ge siemen phillip fuji kodak toshiba
howev maintain healthi reput solid
market share breast imag gynecolog
jan ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
expect revenu increas
sep billion rise
includ divestitur blood
screen unit acquisit cynosur
may earn call announc
million impair charg relat
cynosur busi charg tie
signific churn salesforc
cynosur growth prospect expect
futur top-lin growth come
intern market revenu
vs
expect compani make
larg acquisit near term
net debt capit expect
continu tuck-in acquisit sep
quarter acquir faxitron
look gross margin declin
declin basi point
declin primarili
due rebat refund relat
vitalia tempsur devic shift
 think share trade
ep near fair valu
disappoint year larg due
headwind cynosur exampl
suspend market distribut
vitalia tempsur devic part cynosur
aug light fda concern
claim vagin rejuven
procedur expect low single-digit
growth busi high
single-digit constant currenc growth
busi like pressur
potenti acceler overal growth
capit recent tuck-in acquisit find
downsid risk recommend
target price includ continu weak
perform intern market
competit regulatori pressur
tradit breast health diagnost
target price
ep estim
multipl near middl
averag ratio
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview develop manufactur supplier premium diagnost
product medic imag system surgic product emphasi women health
oper five segment diagnost revenu year end breast health
medic aesthet gyn surgic skelet health sell
servic product combin direct sale servic personnel network
independ distributor sale repres
offer wide rang diagnost product use primarili aid diagnosi human
diseas primari diagnost product includ holx aptima famili assay thinprep system
rapid fetal fibronectin test
breast health product includ broad portfolio breast imag relat product accessori
includ digit mammographi system computer-aid detect cad mammographi
minim invas breast biopsi devic breast biopsi site marker breast biopsi guidanc system
holx advanc breast imag platform dimens util technolog call tomosynthesi
produc imag show multipl contigu slice imag breast
medic aesthet segment offer portfolio aesthet treatment system sculpsur
enabl plastic surgeon dermatologist medic practition perform non-invas
minim invas procedur remov hair treat vascular benign pigment lesion remov
multi-color tattoo revit skin reduc fat laser lipolysi reduc cellulit clear nail
infect toe fungu ablat sweat gland improv gynecolog health
gyn surgic segment make product aim toward gynecolog health novasur
endometri ablat system skelet health segment offer product bone densitomet
imag system use assist perform minim invas surgic procedur
competit landscap holx wide array product face competit varieti
competitor includ competitor even broader product portfolio great brand recognit
current environ manag care economically-motiv buyer consolid among
healthcar provid increas competit declin reimburs rate
increasingli requir compet basi price valu reliabl effici
manufactur supplier broad array light-bas aesthet medic treatment system
product use provid divers rang treatment applic non-invas bodi
contour hair remov tattoo remov skin revit scar reduct well treatment
vascular lesion cynosur busi refer medic aesthet oper separ
januari divest blood screen busi grifol sale price
billion august acquir gen-prob lead maker molecular diagnost product
billion june acquir tct intern co ltd privat held distributor
medic product china acquisit tct provid establish nationwid sale
organ custom support infrastructur china
financi trend revenu grew billion sep billion five-year
cumul annual growth rate compound-annual-growth-rate adjust earn per share vs
five-year compound-annual-growth-rate adjust ep holx free cash flow defin cash
flow oper less capit expenditur neg million compar posit
million given net debt total capit ratio march recent weaker free
cash flow dont expect make larg acquisit near futur howev think
opportunist tuck-in acquisit like
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
neutral sinc novemb technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
posit continu expect
compani sub-industri grow
posit macro environ addit
sub-industri mani product area
histor recession-resist
particularli equip use non-elect
procedur valuat continu high
industri driven expand margin
robust revenu growth compani
industri think lax food
drug administr fda
increas capabl technolog
enabl medic devic manufactur bring
innov product market faster
constant currenc basi expect
revenu sub-industri rise
high-single-digit low-double-digit
percentag driven continu pipelin
innov new product emerg market
expans speed new product
come market increas recent
year success effort
fda reduc approv time medic
devic time see price
pressur incess head wind medic
impact trade war appear mild
far medic equip compani
accord medic devic trade
septemb retaliatori tariff
billion us medic technolog export
although us chines govern
seek lower health care cost provid
equip manufactur insul
industri earlier commentari
medic devic manufactur suggest
impact trade war would manag
provid commentari impact
trade war earn
on-going threat state health
care system current us
administr continu attempt repeal
afford act stop
multipl time gather suffici
number vote pass variou repeal
replac bill recent on-going
lawsuit texa question
constitution
think import watch
mid-term elect novemb
health care appear import topic
hospit spend larg driver medic
equip sale robust
strong us economi
tax cut job act tcja individu
mandat roll think
hospit could see pressur lead
sale pressur medic equip
requir american health
insur without requir
expect lower number american
gener see posit long-term
fundament includ increas global
demand qualiti health care age
popul rise outlay lead
steadi flow innov product
 health equip
sub-index increas vs rise
 composit index year
date septemb
increas composit
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
unit acquisit cynosur rose well growth
forecast howev gross margin fell product mix blood screen
higher margin oper margin declin bp due inclus
cynosur expens encourag sale growth anticip lower
analyst research note compani news
et cfra retain hold opinion share inc
maintain target
ep estim multipl near middl
averag ratio sep-q ep vs
lower estim lower fy sep ep
initi fy ep sep-q sale increas
constant currenc million difficult comparison
divestitur blood screen busi non-recurring royalti
revenu molecular diagnost breast health sale grew constant
medic aesthet declin cc gyn surgic grew
cc acquir cynosur busi continu headwind due
faxitron intend continu priorit
tuck-in acquisit capit alloc /kevin huang cfa
et cfra retain hold opinion share inc
rais target below-p
ep estim multipl near middl
five-year averag ratio jun-q ep vs
higher estim rais fy sep ep
lower fy ep jun-q sale increas
constant currenc million driven growth breast
health intern busi breast health sale grew
constant currenc intern busi grew exclud acquir
cynosur busi constant currenc august
announc departur cfo bob mcmahon agil result chief
account offic karleen oberton promot cfo also
announc acquisit faxitron leader digit specimen
radiographi million expect continu make tuck-in
acquisit like near futur /kevin huang cfa
lower target below-p
ep estim multipl close
holx five-year averag mar-q ep vs
lower estim sep ep estim remain
unchang sale increas million
howev due signific churn holx salesforc aggress
forecast cynosur growth prospect took million
impair charg mar-q relat recent acquir cynosur
busi revenu growth guidanc reduc
posit note intern revenu grew organ
constant currenc basi diagnost revenu exclud divest blood
screen busi declin breast health grew gyn surgic
declin holx capit alloc strategi expect
compani focu tuck-in acquisit supplement exist
rais target line peer
fy sep ep estim set fy
dec-q ep vs ahead estim sale rose
organ growth yet oper margin fell bp gross
margin declin bp due sale blood screen busi
cost rose inclus cynosur medic aesthet
acquisit lift fy sep ep guidanc
lower effect tax rate fy /jeffrey
keep target in-lin peer
forward ep estim jun-q ep vs
estim sale account sale blood screen
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
